新輔助化療對骨肉瘤多藥耐藥相關(guān)蛋白表達的影響分析

黃錚　易偉宏

[摘要] 目的 探究將不同新輔助化療方案應(yīng)用于治療多藥耐藥相關(guān)蛋白在骨肉瘤組織表達中存在的影響。方法 采用RP-PCR技術(shù)以及免疫組化技術(shù)，方便選取該院2015年9月—2018年6月間收入的50例骨肉瘤患者進行檢驗探究，根據(jù)患者的不同化療類型將其分為MMIA方案與DIA方案進行化療，分別命名為MMIA組和DIA組，每組中均錄入25例患者。應(yīng)用不同新輔助化療方案實施前后多藥耐藥相關(guān)蛋白在mRNA以及蛋白水平中造成的變化狀況分析其影響。 結(jié)果 在同一新輔助化療方案的實施前后，以及不同新輔助化療方案的實施期間，腫瘤組織的多藥耐藥蛋白的mRNA以及蛋白表達差異無統(tǒng)計學(xué)意義（t=0.565 2，P=0.574 5）。并且在實施新輔助化療方案后，不同化療方案患者的腫瘤組織中MRP蛋白表達狀況存在差異，MMIA化療組患者化療前的MRP陽性率記錄為84.00%，而化療后的陽性率記錄為88.00%;而DIA組患者化療前MRP的陽性率記錄為84.00%，化療后陽性率仍然為84.00%。組間差異經(jīng)對比分析后，差異無統(tǒng)計學(xué)意義，同時化療前后同組患者的表達狀況差異無統(tǒng)計學(xué)意義（χ2=0.664 5，P=0.414 9）。 結(jié)論 不同新輔助化療方案在應(yīng)用于骨肉瘤多藥耐藥蛋白的治療中，對其蛋白表達的影響較為有限，其主要耐藥性與患者個體狀況以及腫瘤本身特性有較為密切的關(guān)系，對患者進行多藥耐藥蛋白表達檢測，有助于根據(jù)患者的具體狀況進行相應(yīng)的治療，這樣才能保證患者的治療效果，以達到治療目的。

[關(guān)鍵詞] 新輔助化療;骨肉瘤;多藥耐藥;相關(guān)蛋白;影響分析

[中圖分類號] R738.1? ? ? ? ? [文獻標識碼] A? ? ? ? ? [文章編號] 1674-0742（2019）07（a）-0063-04

Analysis of the Effect of Neoadjuvant Chemotherapy on the Expression of Multidrug Resistance-associated Protein in Osteosarcoma

HUANG Zheng， YI Wei-hong

Department of Spinal Surgery， Nanshan District People's Hospital， Shenzhen， Guangdong Province， 518000 China

[Abstract] Objective To investigate the effects of different neoadjuvant chemotherapy regimens on the expression of multidrug resistance-associated proteins in osteosarcoma tissues. Methods RP-PCR and immunohistochemical techniques were used to investigate 50 cases of osteosarcoma patients from September 2015 to June 2018 in our hospital. According to the different types of chemotherapy， patients were convenient selected and divided into MMIA programs and DIA programs. Chemotherapy was performed in the DIA protocol and was named as MMIA and DIA group， with 25 patients enrolled in each group. The effects of multidrug resistance-associated proteins on mRNA and protein levels before and after the implementation of different neoadjuvant chemotherapy regimens were analyzed. Results There was no statistically significant difference in the mRNA and protein expression of multidrug resistance protein in tumor tissues before and after the implementation of the same neoadjuvant chemotherapy regimen and during the implementation of different neoadjuvant chemotherapy regimens（t=0.565 2， P=0.574 5）. And after the implementation of the neoadjuvant chemotherapy regimen， the expression of MRP protein in the tumor tissues of patients with different chemotherapy regimens was different. The positive rate of MRP before chemotherapy in the MMIA chemotherapy group was recorded as 84.00%， and the positive rate after chemotherapy was recorded as 88.00%; The positive rate of MRP before chemotherapy in the DIA group was 84.00%， and the positive rate after chemotherapy was still 84.00%. After the comparison between the groups， there was no statistical difference， and there was no statistically significant difference in the expression of the same group before and after chemotherapy（χ2=0.664 5，P=0.414 9）. Conclusion Different neoadjuvant chemotherapy regimens have limited effects on the expression of multidrug resistance protein in osteosarcoma， and their main drug resistance and individual patient status and tumor characteristics had a close relationship between the detection of multidrug resistance protein expression in patients， and it is helpful to carry out corresponding treatment according to the specific conditions of patients， so as to ensure the therapeutic effect of patients to achieve therapeutic purposes.